Please login to the form below

Not currently logged in
Email:
Password:

UCB’s Mark Bodmer elected to BIA board

Will hold the position for a three-year fixed term

ucb mark bodmerUCB's Mark Bodmer has been elected to the board of UK trade body the BioIndustry Association (BIA).

Bodmer is VP, NewMedicines Therapeutics at UCB, having joined the company in 2012 as head of immunology.

As a board member of the BIA Bodmer will play a role in shaping the policy environment of the UK biotech industry. He will hold the role for three years, starting in January 2015.

Prior to joining UCB Bodmer served as senior VP of immunoinflammation, medicines discovery and development at GlaxoSmithKline.

His background also includes CEO appointments at three start-ups from 1996 to 2007: Hexagen, Lorantis and Biotica.

10th November 2014

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Employee engagement
Route 66: can remote working put two-thirds of us back on the road to engaged employment?
Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Demonstrating the value of HCP self-serve portals
Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....

Infographics